Oncology – Page 19

Long-Term Thyroid Toxicity Burden in Children Who Received Treatment for High-Risk Neuroblastoma

By MedXY 03/11/2026

This review analyzes the significant long-term thyroid toxicity burden in high-risk neuroblastoma survivors, identifying key risk factors such as molecular radiotherapy, tandem myeloablative therapy, and immunotherapy.

Cardiology news Oncology

Targeting CXCR6: A New Therapeutic Frontier in Immune Checkpoint Inhibitor-Induced Myocarditis

By MedXY 03/11/2026

This study identifies CXCR6+ T cells as the primary drivers of immune checkpoint inhibitor-induced myocarditis, especially with anti-LAG-3/PD-1 combinations. Researchers demonstrate that targeting the CXCR6-CXCL16 axis can reduce cardiac inflammation and mortality, offering a promising strategy for managing this life-threatening complication.

Gastroenterology news Oncology

Toxicity as a Proxy for Efficacy: How Immune-Mediated Adverse Events Correlate with Survival in the HIMALAYA Trial

By MedXY 03/11/2026

This post-hoc analysis of the HIMALAYA Phase III trial explores the link between immune-mediated adverse events and overall survival in unresectable HCC, revealing that patients on the STRIDE regimen who experienced imAEs had improved survival outcomes compared to those who did not.

Clinical Updates news Oncology

TAF2 in Hepatocellular Homeostasis and Tumorigenesis: Navigating the 8q24.12 Amplicon in Liver Cancer

By MedXY 03/10/2026

This review explores the dual role of TAF2 as a basal transcription factor essential for hepatocyte survival and an oncogenic driver in hepatocellular carcinoma when overexpressed via 8q24.12 amplification.

Gastroenterology news Oncology

Universal ESD for Large Barrett’s Cancers: Shifting the Paradigm Toward Curative R0 Resection

By MedXY 03/10/2026

A multicenter study demonstrates that prioritizing endoscopic submucosal dissection (ESD) for Barrett’s cancers >15mm significantly improves R0 resection rates and survival, particularly in T1b disease, compared to traditional endoscopic mucosal resection (EMR).

Cardiology news Oncology

GnRH Antagonists May Spare the Heart: Evidence of Reduced Coronary Plaque Progression in Prostate Cancer Patients

By MedXY 03/09/2026

A randomized clinical trial indicates that the GnRH agonist leuprolide significantly accelerates coronary plaque progression compared to the antagonist relugolix in men with prostate cancer, suggesting a potential biological mechanism for differential cardiovascular risk between ADT classes.

Gastroenterology news Oncology

Global Diversity in Autoimmune Gastritis: Deciphering Regional Phenotypes and Neoplastic Risks

By MedXY 03/09/2026

An international multicentre study of 1,240 patients reveals that autoimmune gastritis presentation varies by region, with distinct risk factors—including age, intestinal metaplasia, and extreme hypergastrinemia—driving the development of gastric adenocarcinoma and neuroendocrine tumors.

Gastroenterology news Oncology

New Consensus on APC Mosaicism: Transforming the Diagnosis and Management of Unexplained Polyposis

By MedXY 03/09/2026

A landmark study in Gastroenterology reveals that APC mosaicism accounts for nearly 10% of unexplained colorectal polyposis. New guidelines recommend specific testing thresholds and surveillance strategies to prevent colorectal cancer in these high-risk patients.

news Oncology Otorhinolaryngology

Long-Term Survival Gains with Tislelizumab: Redefining First-Line Therapy for Metastatic Nasopharyngeal Carcinoma

By MedXY 03/09/2026

The 3-year follow-up of the RATIONALE-309 trial demonstrates that first-line tislelizumab plus chemotherapy significantly improves overall survival (45.3 months) in recurrent or metastatic nasopharyngeal carcinoma, identifying B-cell signatures as a key predictor of response.

Gastroenterology news Oncology

Unmasking DARS1: A Dual-Action Driver of Hepatocellular Carcinoma Aggressiveness via SAGA-MYC Signaling

By MedXY 03/08/2026

Researchers have identified DARS1 as a critical oncogenic driver in hepatocellular carcinoma. Beyond its role in protein synthesis, DARS1 enters the nucleus to modulate MYC signaling through the SAGA complex, offering a new therapeutic vulnerability and a potential liquid biopsy biomarker.

Gastroenterology news Oncology

The Tryptophan Tug-of-War: How Faecalibacterium prausnitzii Counteracts Bacteroides fragilis in Colorectal Cancer

By MedXY 03/08/2026

A comprehensive multi-omics study reveals that Faecalibacterium prausnitzii metabolizes tryptophan into picolinic acid, which antagonizes the pro-tumorigenic effects of enterotoxigenic Bacteroides fragilis by down-regulating TCERG1 and CKAP2 genes, suggesting a potential dietary intervention for colorectal cancer.

Gastroenterology news Oncology

Adjuvant Imatinib Significantly Extends Survival and Delays Recurrence in KIT Exon 9-Mutant GIST: Evidence from a Global Multicenter Cohort

By MedXY 03/07/2026

This international multicenter study demonstrates that adjuvant imatinib therapy significantly improves both recurrence-free and overall survival in patients with resected KIT exon 9-mutant GIST, providing clarity on optimal management for this biologically distinct subgroup.

Clinical Updates news Oncology

Optimizing Immunotherapy in Cholangiocarcinoma: Low-Dose Chemotherapy as a Catalyst for Immune Microenvironment Remodeling

By MedXY 03/07/2026

This review examines how low-dose gemcitabine and cisplatin (LDGC) synergize with anti-PD-L1 therapy in intrahepatic cholangiocarcinoma by reprogramming immunosuppressive SPP1+ macrophages and enhancing CD8+ T-cell cytotoxicity through STAT1/STAT3 modulation.

Diabetes & Endocrinology news Oncology

Beyond Mandatory Resection: Active Surveillance Proves Safe for RAS-Positive Thyroid Nodules

By MedXY 03/06/2026

A new study suggests that isolated RAS mutations in Bethesda III and IV thyroid nodules do not always require surgery. With a 34% malignancy rate and low growth incidence, active surveillance emerges as a viable, safe alternative for appropriately selected patients.

$Genomic Therapy Matching in Rare and Refractory Cancers: Clinical Utility and Survival Outcomes from the MoST Program$

Clinical Updates news Oncology

Genomic Therapy Matching in Rare and Refractory Cancers: Clinical Utility and Survival Outcomes from the MoST Program

By MedXY 03/06/2026

This review synthesizes findings from the Australian MoST program, demonstrating that genomically matched therapies significantly improve overall survival in advanced solid tumors only when supported by high-level prospective clinical trial evidence.

Clinical Updates news Oncology

Patient-Centered Outcomes in Geriatric Oncology: Analyzing the Influence of Survival vs. Quality of Life Preferences in the GAP70+ Trial

By MedXY 03/06/2026

A secondary analysis of the GAP70+ trial reveals that while 71.7% of older adults with advanced cancer prioritize quality of life, their clinical outcomes—including survival and toxicity—remain unchanged compared to those prioritizing survival, suggesting a systemic lack of responsiveness to patient goals.

news Oncology Urology

Questioning Routine Hormone Therapy: No Survival Benefit for Low-PSA Recurrent Prostate Cancer Undergoing Postoperative Radiotherapy

By MedXY 03/06/2026

A large-scale individual patient data meta-analysis suggests that adding hormone therapy to postoperative radiotherapy does not improve overall survival for patients with low PSA levels, prompting a re-evaluation of current treatment standards for recurrent prostate cancer.

Dermatology news Oncology

Breaking the Wall: Can Intermittent Chemotherapy Overcome Primary Checkpoint Inhibitor Resistance in Metastatic Melanoma?

By MedXY 03/05/2026

The multicentre phase II PROMIT trial demonstrates that intermittent dacarbazine can sensitize BRAF wildtype metastatic melanoma patients with primary ICI resistance to subsequent ICI rechallenge, yielding an 18% objective response rate and a manageable safety profile.

news Oncology Urology

SURE-02 Trial: Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Enable Bladder Preservation in Muscle-Invasive Disease

By MedXY 03/04/2026

The SURE-02 phase 2 trial demonstrates that a combination of sacituzumab govitecan and pembrolizumab achieves a 39% clinical complete response rate in muscle-invasive bladder cancer, offering a promising bladder-sparing alternative for patients ineligible for cisplatin-based chemotherapy.

Gastroenterology news Oncology

Precision Dosing Without Compromise: UGT1A1 Genotype-Guided Irinotecan Dosing Maintains Survival in Gastrointestinal Cancers

By MedXY 03/04/2026

A multicentre cohort study confirms that upfront 30% irinotecan dose reductions for UGT1A1 poor metabolisers effectively prevent severe toxicity without compromising progression-free or overall survival in colorectal and pancreatic cancer patients.